Boosting the go-to-market strategy and accelerating new product development for a pharma services leader

We partnered with CSafe to help the company serve the global pharma market safely deliver critical therapies to patients around the world by enhancing their go to market capabilities and creating new product offerings.

The Opportunity

CSafe provides cold chain packaging and logistics services designed to maintain high-value, temperature-sensitive biopharmaceutical cargo—a powerful technology built for the cold chain supply chain. With continued scientific advances, there is an increased demand for climate-controlled solutions for pharmaceutical transport. The company was well-positioned to service the global supply chain needs of the growing biopharmaceutical market.

The challenge

At the time of acquisition, CSafe had a high-quality product but had not yet penetrated most of the Global Top 20 pharma companies. The company primarily served the North American market, but had low awareness in EMEA and APAC regions.

The Results

We worked with CSafe to focus on Global Top 20 pharma companies—a key market opportunity. By leveraging our vast network of pharma relationships and collaborating with the management team to build a robust go-to-market strategy, install rigorous measurement capabilities and develop in-depth product and sales trainings, our partnership produced strong results.

Twofold capacity increase

The company more than doubled both its production and sales capacities to improve global coverage in key markets. It now serves almost all major pharmaceutical companies in the world.

Global impact

In recent years, CSafe was able to distribute more than 6 billion doses of the COVID-19 vaccine worldwide.

Related content

THL Announces Agreement to Acquire Headlands Research from KKR
Press Release
THL Announces Agreement to Acquire Headlands Research from KKR 

Strategic Partnership to Advance Site Network Expansion and Accelerate Clinical Trial Innovation LAKE WORTH, Fla. & NEW YORK–(BUSINESS WIRE)–THL Partners (“THL”), a premier private equity firm investing in middle market growth companies, today announced the entry into a definitive agreement to acquire Headlands Research (“Headlands” or “the Company”), a leading multinational network of clinical trial sites, from funds managed
Forward Through Uncertainty: What Biopharma Leaders Are Saying About the FDA, R&D Investment
Insights
Forward Through Uncertainty: What Biopharma Leaders Are Saying About the FDA, R&D Investment 

Key Takeaways Recent FDA changes have generated uncertainty across the biopharma sector, with questions mounting around approval timelines, shifting trial expectations, and regulatory consistency. In May and June 2025, THL surveyed 100 biopharma decision-makers—spanning early-stage biotechs to top 50 pharma companies—to better understand how today’s regulatory and market dynamics are influencing R&D investment. Most respondents plan to maintain

Healthcare (HC)
From One to Twenty: How CSafe Became a Leader in the Pharma Cold Chain
Insights
From One to Twenty: How CSafe Became a Leader in the Pharma Cold Chain 

In the world of pharmaceutical logistics, maintaining the precise temperature of biologically based therapies like the Covid vaccine is mission critical. Even minor temperature fluctuations can compromise the efficacy of life-saving drugs. CSafe, a leading provider of cold chain shipping solutions, ensures that pharmaceutical products reach their destination without deviation from required temperature set points. Its

Healthcare (HC)

For a list of all portfolio company investments made by THL since its inception, please click here.

Want to know more?

Learn more about our integrated approach to private equity

How we invest